2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.080 Josh Biber NACLC23 Abstract

PP01.080 Josh Biber NACLC23 Abstract

Pdf Summary

This retrospective observational study aimed to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK non-small cell lung cancer (NSCLC) who were treated with ALK inhibitors. The study spanned from 2019 to 2022 and involved monthly surveys completed by participants to assess quality of life (QoL) for up to 24 months. One objective of the study was to compare the patient self-reported QoL status between those receiving brigatinib and those receiving alectinib.<br /><br />The study included 94 enrolled patients, with 29 receiving brigatinib and 65 receiving alectinib. The majority of patients reported having stage 4 cancer. The results showed that brigatinib had greater reductions in pain-related scores compared to alectinib during the first 360 days of treatment. Specifically, brigatinib had greater reductions in pain in the chest, pain in the arm or shoulder, pain in other parts of the body, and pain relief after medication in 18 of the 24 time periods examined. At the 180-day and 270-day time points, brigatinib had greater reductions in 8 out of 14 scores of the EORTC QLQ-LC13. Similarly, at the 360-day mark, brigatinib had greater reductions in 10 out of 14 scores compared to alectinib.<br /><br />Based on the findings, the study suggests that brigatinib may be better tolerated than alectinib in terms of pain relief after medication and the absence of pain in other parts of the body. The use of patient-reported outcomes provides valuable insight into the impact of therapy on the quality of life experienced by patients with metastatic ALK NSCLC. These findings may help inform treatment decisions and improve patient care.

Keywords

retrospective observational study

patient-reported outcomes

metastatic ALK non-small cell lung cancer

ALK inhibitors

quality of life

QoL

brigatinib

alectinib

pain-related scores

EORTC QLQ-LC13